Mobile

An open-label, single-arm, phase IV study assessing the immunogenicity and safety of ZOSTAVAX at minimum release specification approaching expiry potency in subjects ≥50 years old

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006532-66

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate whether or not ZOSTAVAX® at minimum release specification and approaching expiry potency elicits an acceptable VZV antibody fold rise (gpELISA) from pre-vaccination to 4 weeks post-vaccination

Critère d'inclusion

  • Not applicable_Healthy volunteers_Up to 50 years of age

Liens